GPCRs and Insulin Receptor Signaling in Conversation: Novel Avenues for Drug Discovery.
Curr Top Med Chem
; 19(16): 1436-1444, 2019.
Article
em En
| MEDLINE
| ID: mdl-31512997
ABSTRACT
Type 2 diabetes is a major health issue worldwide with complex metabolic and endocrine abnormalities. Hyperglycemia, defects in insulin secretion and insulin resistance are classic features of type 2 diabetes. Insulin signaling regulates metabolic homeostasis by regulating glucose and lipid turnover in the liver, skeletal muscle and adipose tissue. Major treatment modalities for diabetes include the drugs from the class of sulfonyl urea, Insulin, GLP-1 agonists, SGLT2 inhibitors, DPP-IV inhibitors and Thiazolidinediones. Emerging antidiabetic therapeutics also include classes of drugs targeting GPCRs in the liver, adipose tissue and skeletal muscle. Interestingly, recent research highlights several shared intermediates between insulin and GPCR signaling cascades opening potential novel avenues for diabetic drug discovery.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Receptor de Insulina
/
Transdução de Sinais
/
Receptores Acoplados a Proteínas G
/
Diabetes Mellitus Tipo 2
/
Descoberta de Drogas
/
Hipoglicemiantes
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Top Med Chem
Assunto da revista:
QUIMICA
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Estados Unidos